ThromboGenics NV (NYSE Euronext Brussels: THR), a biopharmaceutical company focused on the development of ocular treatments has announced that the Belgian tax authorities have granted the company a positive ruling under the “patent income deduction regime”. The Belgium-based incentivisation scheme should allow ThromboGenics to benefit from a reduced tax rate for all patent related income arising from the company’s lead ocriplasmin product. On July 27th, the company announced it had received a US Food and Drug Administration (FDA) Dermatologic and Ophthalmic Drugs Advisory Committee recommendation that ocriplasmin be approved for the treatment of symptomatic vitreomacular adhesion (VMA).